Kemena is a historic turning point from imitation to creation in China

According to the 2013 drug review report issued by CFDA drug review center, the largest proportion of tumor drugs in clinical research, no matter the international multi center clinical trial application or the domestic clinical research application, the largest proportion is in the field of tumor treatment From 2011 to 2012, it accounted for 30% - 40%, and in 2013, it exceeded 40% However, most of these drugs are focused on non cytotoxic targeted agents For small molecule targeted drugs, almost all of them are products that have been on the market or have been modified on the basis of products that have been developed There is almost no new mechanism or new structure of small molecule targeted drug products Cheng Shu, academician of the Chinese Academy of engineering, said that in the same tumor, the mechanism of primary and metastasis is different, so we haven't found a breakthrough path for a long time, but recent research in the United States found that the DNA left by tumor circulating cells can find a target, "the discovery of this key point will bring historic changes to tumor drugs." Cheng Shujun said According to Sang Guowei, academician of the Chinese Academy of engineering, the reasons for the failure of molecular targeted anti-tumor drug research and development in China in the past decade are as follows: insufficient understanding of the high heterogeneity of tumors; weak awareness of the selection of sensitive populations; lack of research on the mechanism of drug resistance; limitations in the strategy of combined drug use; insufficient attention to non classical side effects According to Cheng Shu, Chinese people can't always follow in the research and development of tumor drugs If they want to compete for the right to speak in international drug research and development, they should seize the opportunity of disease transformation At present, our goal in cancer treatment is not to kill tumors and prolong the survival period, but to really give cancer the meaning of chronic disease, so that all tumor patients can survive with cancer According to Chen Zhu, vice chairman of the Standing Committee of the National People's Congress, ektinib hydrochloride is a "two bombs and one star" for the people's livelihood of China This is the first small molecule targeted anti-tumor drug with completely independent intellectual property rights in China, breaking the myth that foreign enterprises monopolize the tumor targeted drug market, which is known as "the affordable targeted drug for Chinese patients" The reporter learned that at present, one cycle of libitum + carboplatin is 24870 yuan, one cycle of gemcitabine + carboplatin is 7200 yuan, and one cycle cost of Taxotere + platinum is 11694 yuan Yiruisha 5500 / box; Troika 4300 / box; Kemena 2753 / box Among them, 196 were imported carboplatin, and 1500 yuan was used as adjuvant every cycle Up to now, there are 32 clinical studies registered on clinicaltrials.gov by exetinib hydrochloride, and the upcoming contract study may confirm that exetinib hydrochloride is the first-line drug for non-small cell lung cancer (NCLC) The previously concluded contract study compared the efficacy and safety of Kemena and Iressa in the second and third line treatment of advanced non-small cell lung cancer patients.